Strategic Delivery Solutions (“SDS Rx” or the “Company”) is a healthcare focused supply chain solutions provider focused on the long-term care (“LTC”) the pharmacy market, specializing in the movement of pharmaceuticals from wholesale distributors to pharmacies and hospitals and from LTC pharmacies to facilities and patients.
SDS Rx was initially designed to target the pharmaceutical distribution sector and offer pharmaceutical distributors, pharmacies, labs and healthcare systems a combination of proven process, enhanced technology, and a local delivery network on a national scale. Building on that model, the Company has achieved consistent revenue growth, establishing a national footprint while setting the local benchmark for delivery accuracy and establishing itself as the undisputed thought leader in last mile healthcare delivery and logistics. With fresh capital through its financial partnership with HCI Equity Partners (“HCI”) in 2018, SDS Rx is now well positioned to accelerate its growth through a disciplined acquisition strategy and explore expansion opportunities.
G2 served as the buy-side advisor to SDS Rx with respect to the Medical Delivery Services (“MDS”) acquisition. After serving as the Company’s financial advisor with HCI’s recapitalization of the business in 2018, G2 was a natural fit to support additional acquisition search activities within the healthcare logistics marketplace.
The acquisition of MDS was successfully executed in June 2020, building density in existing footprint, while also bringing SDS Rx into new geographies and providing access to a new healthcare end market. Furthermore, G2 has successfully sourced two targets in addition to MDS that are currently under LOI.